PAR 5.77% 24.5¢ paradigm biopharmaceuticals limited..

research reports and media, page-3960

  1. 4,109 Posts.
    lightbulb Created with Sketch. 1425
    Altered properties of amyloidogenic prion protein in genetic Creutzfeldt–Jakob disease with PRNP V180I mutation in response to pentosan polysulfate
    https://onlinelibrary.wiley.com/doi/full/10.1111/bpa.13197

    "Both PPS-treated cases showed long survival time over 5 years from onset and increased PrP deposition with a characteristic pattern of coarse granular depositions and congophilic PrP microspheres, whereas the cases without PPS showed around 1-year survival from onset and relatively mild neuronal loss and synaptic PrP deposition."

    "These unique biochemical and histopathological changes may reflect the progression of V180I gCJD and its modification by PPS, suggesting the possible existence of toxic PrP-oligomer in the pathophysiology of V180I gCJD and beneficial effects of PPS toward the aggregation and detoxication of toxic PrP-oligomer."
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
24.5¢
Change
-0.015(5.77%)
Mkt cap ! $85.80M
Open High Low Value Volume
28.0¢ 29.0¢ 24.0¢ $969.3K 3.648M

Buyers (Bids)

No. Vol. Price($)
6 34182 24.0¢
 

Sellers (Offers)

Price($) Vol. No.
24.5¢ 24689 1
View Market Depth
Last trade - 16.10pm 18/09/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.